Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2289 | Masked Saline Placebo Wiki | 1.00 |
| drug1047 | Convalescent Plasma Wiki | 0.19 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
Most patients undergoing a cardiovascular procedure need an ICU-bed during the hospitalization and therefore it is possible that for the unforeseen future, because of the Covid-19 crisis, many patients will stay on the waiting list for many months to come. There are some studies showing an increased mortality associated with an increased waiting time for the patients on the waiting list for an elective cardiac surgery. However, there is no data on the evolution of the morbidity, the quality of life and the symptomatology of the patients waiting for an elective operation. Also it is not clear whether the period of waiting for an elective cardiovascular operation would impact the morbidity or the mortality of the planned operation at later stage. Furthermore, there is a plethora of studies on risk factors associated with the perioperative morbidity and mortality in general. Therefore, the rationale of the current study is to evaluate whether Digital Cardiac Counseling (DCC) would improve outcomes of the patients waiting for an elective cardiac operation. At the DCC platform, there will be assessments of cardiovascular symptoms, Covid-19 prevention for cardiovascular patients, smoking cessation, anxiety relief, exercise stimulation, pulmonary rehabilitation and diet adjustments. This will be done by means of questionnaires and E-consults.
Description: Major Adverse Cardiovascular Events defined as Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure and/or fo earlier planned intervention
Measure: MACEs Time: Cumulative incidence (from inclusion) at 1 year postoperativelyDescription: all-cause mortality
Measure: Mortality Time: Before the scheduled date of the operation, at 30 days, in-hospital (at 30 days or during the same hospitalization for the planned procedure), at one-year postoperatively and cumulative from inclusion at 1-year postoperativelyDescription: Mortality caused by cardiovascular disease
Measure: Cardiovascular-related mortality Time: Before the scheduled date of the operation, at one-year postoperatively and cumulative from inclusion at 1-year postoperativelyDescription: Mortality caused by Covid-19 infection and/or related complications
Measure: Covid-19 related mortality Time: Before the scheduled date of the operation, at one-year postoperatively and cumulative from inclusion at 1-year postoperativelyDescription: Measured using SF (Short Form) 36 Health Survey
Measure: Health-related quality of life Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 monthsDescription: New York Heart Association Functional Classification
Measure: NYHA Functional classification Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 monthsDescription: Grading of angina pectoris
Measure: CCS (Canadian Cardiovascular Society grading of angina pectoris) Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 monthsDescription: Major Adverse Cardiovascular Events defined as Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure and/or fo earlier planned intervention
Measure: MACEs Time: during waiting time measured before the scheduled date of the operation, at 1-year postoperativelyDescription: Respiratory failure, pneumonia, septicemia, renal failure, myocardial infarction, stroke, atrial fibrillation, pacemaker implantation, re-operation, delirium, wound infection, urinary tract infection and pressure ulcers
Measure: Perioperative complications Time: during waiting time measured before the scheduled date of the operation, at 30 days postoperatively and at 90 days postoperativelyDescription: from surgery until discharge in days
Measure: Hospital length of stay Time: from the admission to the hospital untill discharge from the hospital, assessed up to 12 monthsDescription: measured in hours from arrival in ICU until extubation
Measure: Time on mechanical ventilation Time: from the admission to the ICU untill discharge from the ICU, assessed up to 12 monthsDescription: whether patient is active smoking
Measure: Smoking status Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 monthsDescription: Measured using HADS (Hospital Anxiety and Depression Scale) score
Measure: Anxiety and Depression Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 monthsDescription: the percentage of patients taking part in postoperative cardiac rehabilitation
Measure: Participation in postoperative cardiac rehabilitation Time: postoperatively at 3 months, at 6 months and at 12 monthsDescription: Percentage BMI<20 or BMI>30
Measure: Body-Mass Index (BMI) Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 monthsDescription: Unplanned visits to emergency department
Measure: Number of participants with unplanned visits Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 monthsDescription: Total costs of the whole treatment process
Measure: Healthcare costs Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports